Biotechnology
Build Your Comparison
Side-by-side financial analysisStock Comparison
PMN vs PRTA vs ARVN vs KO
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Beverages - Non-Alcoholic
PMN vs PRTA vs ARVN vs KO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Beverages - Non-Alcoholic |
| Market Cap | $68M | $432M | $489M | $355.61B |
| Revenue (TTM) | $0.00 | $58M | $89M | $49.28B |
| Net Income (TTM) | $-41M | $-151M | $-221M | $13.70B |
| Gross Margin | — | 46.8% | 97.4% | 61.7% |
| Operating Margin | — | -217.9% | -279.3% | 29.3% |
| Forward P/E | — | 176.7x | — | 25.3x |
| Total Debt | $0.00 | $14M | $9M | $45.49B |
| Cash & Equiv. | $6M | $308M | $143M | $10.27B |
PMN vs PRTA vs ARVN vs KO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| ProMIS Neuroscience… (PMN) | 100 | 4.3 | -95.7% |
| Prothena Corporatio… (PRTA) | 100 | 78.9 | -21.1% |
| Arvinas, Inc. (ARVN) | 100 | 22.6 | -77.4% |
| The Coca-Cola Compa… (KO) | 100 | 184.9 | +84.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PMN vs PRTA vs ARVN vs KO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PMN is the #2 pick in this set and the best alternative if income & stability is your priority.
- beta 1.11
- Beta 1.11 vs PRTA's 1.50
PRTA is the clearest fit if your priority is momentum.
- +62.7% vs PMN's -20.4%
ARVN is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.14, Low D/E 2.1%, current ratio 4.92x
- Beta 1.14, current ratio 4.92x
KO carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 1.9%, EPS growth 23.6%, 3Y rev CAGR 3.7%
- 121.1% 10Y total return vs ARVN's -52.8%
- 1.9% revenue growth vs PRTA's -92.8%
- Better valuation composite
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 1.9% revenue growth vs PRTA's -92.8% | |
| Value | Better valuation composite | |
| Quality / Margins | 27.8% margin vs PRTA's -260.9% | |
| Stability / Safety | Beta 1.11 vs PRTA's 1.50 | |
| Dividends | 2.5% yield; 56-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +62.7% vs PMN's -20.4% | |
| Efficiency (ROA) | 13.1% ROA vs PMN's -151.0% |
PMN vs PRTA vs ARVN vs KO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
PMN vs PRTA vs ARVN vs KO — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
KO leads in 4 of 6 categories
ARVN leads 1 • PMN leads 0 • PRTA leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
KO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
KO and PMN operate at a comparable scale, with $49.3B and $0 in trailing revenue. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to PRTA's -2.6%. On growth, PRTA holds the edge at +17.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $58M | $89M | $49.3B |
| EBITDAEarnings before interest/tax | -$41M | -$124M | -$245M | $15.5B |
| Net IncomeAfter-tax profit | -$41M | -$151M | -$221M | $13.7B |
| Free Cash FlowCash after capex | -$35M | -$81M | -$257M | $12.6B |
| Gross MarginGross profit ÷ Revenue | — | +46.8% | +97.4% | +61.7% |
| Operating MarginEBIT ÷ Revenue | — | -2.2% | -2.8% | +29.3% |
| Net MarginNet income ÷ Revenue | — | -2.6% | -2.5% | +27.8% |
| FCF MarginFCF ÷ Revenue | — | -140.6% | -2.9% | +25.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +17.1% | -91.7% | +12.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +76.0% | +153.6% | -178.9% | +18.2% |
Valuation Metrics
ARVN leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $68M | $432M | $489M | $355.6B |
| Enterprise ValueMkt cap + debt − cash | $61M | $138M | $355M | $390.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.46x | -1.82x | -5.92x | 27.18x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 176.66x | — | 25.27x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 2.43x |
| EV / EBITDAEnterprise value multiple | — | — | — | 26.39x |
| Price / SalesMarket cap ÷ Revenue | — | 44.60x | 1.86x | 7.42x |
| Price / BookPrice ÷ Book value/share | — | 1.58x | 1.13x | 10.40x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 67.15x |
Profitability & Efficiency
KO leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-2 for PMN. ARVN carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs PMN's 0/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.4% | -49.9% | -44.4% | +41.1% |
| ROA (TTM)Return on assets | -151.0% | -42.3% | -28.4% | +13.1% |
| ROICReturn on invested capital | — | -21.0% | -22.4% | +15.8% |
| ROCEReturn on capital employed | -5.2% | -47.0% | -16.0% | +17.3% |
| Piotroski ScoreFundamental quality 0–9 | 0 | 1 | 4 | 7 |
| Debt / EquityFinancial leverage | — | 0.05x | 0.02x | 1.33x |
| Net DebtTotal debt minus cash | -$6M | -$294M | -$134M | $35.2B |
| Cash & Equiv.Liquid assets | $6M | $308M | $143M | $10.3B |
| Total DebtShort + long-term debt | $0 | $14M | $9M | $45.5B |
| Interest CoverageEBIT ÷ Interest expense | — | — | — | 10.70x |
Total Returns (Dividends Reinvested)
KO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KO five years ago would be worth $16,560 today (with dividends reinvested), compared to $363 for PMN. Over the past 12 months, PRTA leads with a +62.7% total return vs PMN's -20.4%. The 3-year compound annual growth rate (CAGR) favors KO at 13.7% vs PMN's -56.0% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +45.0% | -10.3% | -33.9% | +20.3% |
| 1-Year ReturnPast 12 months | -20.4% | +62.7% | +0.1% | +17.2% |
| 3-Year ReturnCumulative with dividends | -91.5% | -88.7% | -73.7% | +47.0% |
| 5-Year ReturnCumulative with dividends | -96.4% | -82.7% | -91.0% | +65.6% |
| 10-Year ReturnCumulative with dividends | -91.4% | -82.0% | -52.8% | +121.1% |
| CAGR (3Y)Annualised 3-year return | -56.0% | -51.7% | -35.9% | +13.7% |
Risk & Volatility
KO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than PRTA's 1.50 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs PMN's 26.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.11x | 1.50x | 1.14x | -0.20x |
| 52-Week HighHighest price in past year | $39.75 | $11.80 | $14.51 | $84.04 |
| 52-Week LowLowest price in past year | $6.27 | $4.95 | $6.06 | $65.35 |
| % of 52W HighCurrent price vs 52-week peak | +26.0% | +69.9% | +52.2% | +98.3% |
| RSI (14)Momentum oscillator 0–100 | 51.8 | 35.6 | 24.1 | 60.6 |
| Avg Volume (50D)Average daily shares traded | 34K | 447K | 794K | 12.7M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: PMN as "Buy", PRTA as "Buy", ARVN as "Buy", KO as "Buy". Consensus price targets imply 130.3% upside for PRTA (target: $19) vs 4.2% for KO (target: $86). KO is the only dividend payer here at 2.46% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $18.00 | $19.00 | $14.75 | $86.13 |
| # AnalystsCovering analysts | 2 | 28 | 26 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +2.5% |
| Dividend StreakConsecutive years of raises | — | — | — | 56 |
| Dividend / ShareAnnual DPS | — | — | — | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +18.8% | +0.2% |
KO leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ARVN leads in 1 (Valuation Metrics).
PMN vs PRTA vs ARVN vs KO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PMN or PRTA or ARVN or KO a better buy right now?
For growth investors, The Coca-Cola Company (KO) is the stronger pick with 1.
9% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate ProMIS Neurosciences, Inc. (PMN) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PMN or PRTA or ARVN or KO?
On forward P/E, The Coca-Cola Company is actually cheaper at 25.
3x.
03Which is the better long-term investment — PMN or PRTA or ARVN or KO?
Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.
6%, compared to -96. 4% for ProMIS Neurosciences, Inc. (PMN). Over 10 years, the gap is even starker: KO returned +121. 1% versus PMN's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PMN or PRTA or ARVN or KO?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
20β versus Prothena Corporation plc's 1. 50β — meaning PRTA is approximately -850% more volatile than KO relative to the S&P 500. On balance sheet safety, Arvinas, Inc. (ARVN) carries a lower debt/equity ratio of 2% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.
05Which is growing faster — PMN or PRTA or ARVN or KO?
By revenue growth (latest reported year), The Coca-Cola Company (KO) is pulling ahead at 1.
9% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Arvinas, Inc. grew EPS 53. 8% year-over-year, compared to -922. 2% for ProMIS Neurosciences, Inc.. Over a 3-year CAGR, ARVN leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PMN or PRTA or ARVN or KO?
The Coca-Cola Company (KO) is the more profitable company, earning 27.
3% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — ARVN leads at 98. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PMN or PRTA or ARVN or KO more undervalued right now?
On forward earnings alone, The Coca-Cola Company (KO) trades at 25.
3x forward P/E versus 176. 7x for Prothena Corporation plc — 151. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRTA: 130. 3% to $19. 00.
08Which pays a better dividend — PMN or PRTA or ARVN or KO?
In this comparison, KO (2.
5% yield) pays a dividend. PMN, PRTA, ARVN do not pay a meaningful dividend and should not be held primarily for income.
09Is PMN or PRTA or ARVN or KO better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
20), 2. 5% yield, +121. 1% 10Y return). Prothena Corporation plc (PRTA) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, PRTA: -82. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PMN and PRTA and ARVN and KO?
These companies operate in different sectors (PMN (Healthcare) and PRTA (Healthcare) and ARVN (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
KO pays a dividend while PMN, PRTA, ARVN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.